{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T07:08:31Z","timestamp":1722496111480},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T00:00:00Z","timestamp":1538697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5,30]]},"DOI":"10.1093\/cid\/ciy830","type":"journal-article","created":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T18:12:10Z","timestamp":1538158330000},"page":"1990-1992","source":"Crossref","is-referenced-by-count":5,"title":["Has the Optimal Therapy for Invasive Candidiasis Now Been Defined?"],"prefix":"10.1093","volume":"68","author":[{"given":"David","family":"Andes","sequence":"first","affiliation":[{"name":"Department of Medicine and Microbiology and Immunology, University of Wisconsin, Madison"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,10,5]]},"reference":[{"key":"2019053001002165200_CIT0001","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1128\/CMR.00029-06","article-title":"Epidemiology of invasive candidiasis: a persistent public health problem","volume":"20","author":"Pfaller","year":"2007","journal-title":"Clin Microbiol Rev"},{"key":"2019053001002165200_CIT0002","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1306801","article-title":"Multistate point-prevalence survey of health care-associated infections","volume":"370","author":"Magill","year":"2014","journal-title":"N Engl J Med"},{"key":"2019053001002165200_CIT0003","first-page":"794","article-title":"Invasive candidiasis","volume":"374","author":"Kullberg","year":"2016","journal-title":"N Engl J Med"},{"key":"2019053001002165200_CIT0004","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/tid.12613","article-title":"The epidemiology and outcomes of invasive Candida infections among organ transplant recipients in the United States: results of the Transplant-Associated Infection Surveillance Network (TRANSNET)","volume":"18","author":"Andes","year":"2016","journal-title":"Transpl Infect Dis"},{"key":"2019053001002165200_CIT0005","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s10096-009-0843-0","article-title":"Factors related to survival and treatment success in invasive candidiasis or candidemia: a pooled analysis of two large, prospective, micafungin trials","volume":"29","author":"Horn","year":"2010","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2019053001002165200_CIT0006","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/cid\/cis021","article-title":"Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials","volume":"54","author":"Andes","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2019053001002165200_CIT0007","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1086\/504810","article-title":"Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study","volume":"43","author":"Garey","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2019053001002165200_CIT0008","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1128\/AAC.49.9.3640-3645.2005","article-title":"Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality","volume":"49","author":"Morrell","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2019053001002165200_CIT0009","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/cid\/cis305","article-title":"Septic shock attributed to Candida infection: importance of empiric therapy and source control","volume":"54","author":"Kollef","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2019053001002165200_CIT0010","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1056\/NEJMoa066906","article-title":"Anidulafungin versus fluconazole for invasive candidiasis","volume":"356","author":"Reboli","year":"2007","journal-title":"N Engl J Med"},{"key":"2019053001002165200_CIT0011","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1086\/520980","article-title":"Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis","volume":"45","author":"Pappas","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2019053001002165200_CIT0012","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa021585","article-title":"Comparison of caspofungin and amphotericin B for invasive candidiasis","volume":"347","author":"Mora-Duarte","year":"2002","journal-title":"N Engl J Med"},{"key":"2019053001002165200_CIT0013","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(07)60605-9","article-title":"Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial","volume":"369","author":"Kuse","year":"2007","journal-title":"Lancet"},{"key":"2019053001002165200_CIT0014","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/S0140-6736(05)67490-9","article-title":"Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial","volume":"366","author":"Kullberg","year":"2005","journal-title":"Lancet"},{"key":"2019053001002165200_CIT0015","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1056\/NEJM199411173312001","article-title":"A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute","volume":"331","author":"Rex","year":"1994","journal-title":"N Engl J Med"},{"key":"2019053001002165200_CIT0016","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1086\/374850","article-title":"A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects","volume":"36","author":"Rex","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2019053001002165200_CIT0017","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/BF01713042","article-title":"A randomized study comparing fluconazole with amphotericin B\/5-flucytosine for the treatment of systemic Candida infections in intensive care patients","volume":"24","author":"Abele-Horn","year":"1996","journal-title":"Infection"},{"key":"2019053001002165200_CIT0018","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/clinids\/23.5.964","article-title":"Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature","volume":"23","author":"Anaissie","year":"1996","journal-title":"Clin Infect Dis"},{"key":"2019053001002165200_CIT0019","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/BF01726360","article-title":"Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group","volume":"16","author":"Phillips","year":"1997","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2019053001002165200_CIT0020","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.4065\/83.9.1011","article-title":"Treatment of invasive Candidal infections: systematic review and meta-analysis","volume":"83","author":"Gafter-Gvili","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"2019053001002165200_CIT0021","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1476-0711-8-23","article-title":"Antifungal treatment for invasive Candida infections: a mixed treatment comparison meta-analysis","volume":"8","author":"Mills","year":"2009","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"2019053001002165200_CIT0022","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1128\/AAC.44.4.1108-1111.2000","article-title":"Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans","volume":"44","author":"Ernst","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"2019053001002165200_CIT0023","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ1194","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2019053001002165200_CIT0024","article-title":"Isavuconazole versus caspofungin in the treatment of candidemia and other invasive Candida infections: the ACTIVE trial","author":"Kullberg","journal-title":"Clin Infect Dis"},{"key":"2019053001002165200_CIT0025","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1128\/JCM.00863-13","article-title":"In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds","volume":"51","author":"Pfaller","year":"2013","journal-title":"J Clin Microbiol"},{"key":"2019053001002165200_CIT0026","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"2019053001002165200_CIT0027","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2019053001002165200_CIT0028","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1128\/AAC.50.4.1570-1572.2006","article-title":"Voriconazole therapeutic drug monitoring","volume":"50","author":"Smith","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2019053001002165200_CIT0029","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/524669","article-title":"Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes","volume":"46","author":"Pascual","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2019053001002165200_CIT0030","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/sj.bmt.1704828","article-title":"Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients","volume":"35","author":"Trifilio","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"2019053001002165200_CIT0031","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2146\/ajhp100423","article-title":"Antifungal use in hospitalized adults in U.S. academic health centers","volume":"68","author":"Pakyz","year":"2011","journal-title":"Am J Health Syst Pharm"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/68\/12\/1990\/28739309\/ciy830.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T01:00:34Z","timestamp":1559178034000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/68\/12\/1990\/5115694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,5]]},"references-count":31,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2018,10,5]]},"published-print":{"date-parts":[[2019,5,30]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciy830","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,6,15]]},"published":{"date-parts":[[2018,10,5]]}}}